Health Care • Medical/Dental Instruments
$41.98 ▼ -0.71
(-1.66%)
MKT CAP: $61.87B • VOL: 22.47M
52W L $40 52W H $106
BSX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $20.07B | $16.75B | $14.24B |
| YoY Revenue Growth % | +19.9% | +17.6% | — |
| Gross Profit | $13.85B | $11.49B | — |
| Gross Margin % | 69.0% | 68.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $3.61B | $2.60B | $2.34B |
| Operating Margin % | 18.0% | 15.5% | 16.5% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | $4.31B | $3.23B | $2.86B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.53B | $3.44B | $2.50B |
| Capital Expenditures (CapEx) | $876.0M | $790.0M | $640.8M |
| Free Cash Flow (FCF) | $3.66B | $2.65B | $1.86B |
| FCF Margin % | 18.2% | 15.8% | 13.1% |
| Return on Invested Capital (ROIC %) | 8.8% | 6.7% | 9.0% |
| Cash & Short-Term Equivalents | $1.97B | $414.0M | — |
| Total Debt (Short + Long Term) | $10.22B | $9.22B | $7.96B |
| Total Stockholders' Equity | $24.23B | $21.77B | $16.33B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BSX.